Skip to main content

Table 1 Effectiveness of DDR mutations in predicting ICI efficacy in solid tumors

From: The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Clinical endpoint

DDR mutation

ICI

Cancer type

Wild type

Mutation type

Refs

ORR

BRCA1/2

Pembrolizumab

Melanoma

5.0%

12.0%

[58]

PRKDC

Anti-CTLA-4 antibody+anti-PD-1 antibody

NSCLC

32.3%

66.7%

[68]

PRKDC

Anti-CTLA-4 antibody

Metastatic melanoma

14.6%

33.3%

[68]

DDR mutation

Anti-PD-1/PD-L1 antibodies

Urothelial cancer

18.8%

67.9%

[45]

PFS

PRKDC

Anti-CTLA-4 antibody+anti-PD-1 antibody

NSCLC

6.8 m

NR

[68]

OS

POLE/POLD1

ICI

Solid tumors

18.0 m

34.0 m

[66]

TP53 + ATM

ICI

NSCLC

2.8 m–22.0 m

22.1 m-NR

[67]

  1. Abbreviations: ORR Objective response rate, PFS Progression-free survival, OS Overall survival, NR Not reached